$GMTH
GMTech Inc.

2024 Q2 Form 10-Q Financial Statement

#000168316824004159 Filed on June 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue $12.00K $22.80K
YoY Change -76.0%
Cost Of Revenue $5.000K $4.500K
YoY Change -75.0%
Gross Profit $7.000K $18.30K
YoY Change -76.67%
Gross Profit Margin 58.33% 80.26%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $30.11K $16.85K
YoY Change -4.41%
Operating Profit -$23.11K $1.452K
YoY Change 1438.75%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$23.11K $1.452K
YoY Change 1438.75%
Income Tax $469.00
% Of Pretax Income 32.3%
Net Earnings -$23.11K $983.00
YoY Change 1438.75%
Net Earnings / Revenue -192.6% 4.31%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 7.333M shares 5.000M shares
Diluted Shares Outstanding 7.333M shares 5.000M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $124.4K $5.951K $22.10K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $4.000K $0.00
Other Receivables $0.00
Total Short-Term Assets $130.5K $8.119K $24.27K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $130.5K $8.119K $24.27K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $130.5K $8.119K $24.27K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.802K $5.263K $4.594K
YoY Change
Accrued Expenses $0.00 $0.00 $3.000K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.80K $5.263K $22.39K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.80K $5.263K $22.39K
Total Long-Term Liabilities
Total Liabilities $10.80K $5.263K $22.39K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$20.76K $2.356K $1.373K
YoY Change
Common Stock $1.200K $500.00 $500.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $119.7K $2.856K $1.873K
YoY Change
Total Liabilities & Shareholders Equity $130.5K $8.119K $24.27K
YoY Change

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$23.11K $983.00
YoY Change 1438.75%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$16.15K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -$16.15K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -$16.15K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$16.15K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2024Q2 NONE Related Party Payable
RelatedPartyPayable
2000 usd
CY2023Q4 NONE Related Party Payable
RelatedPartyPayable
0 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
0 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3000 usd
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14800 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
10802 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22394 usd
CY2024Q2 us-gaap Liabilities
Liabilities
10802 usd
CY2023Q4 us-gaap Liabilities
Liabilities
22394 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5000000 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1200 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
500 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
139300 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20756 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1373 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
119744 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1873 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
130546 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24267 usd
CY2023Q2 us-gaap Revenues
Revenues
50000 usd
us-gaap Revenues
Revenues
34800 usd
us-gaap Revenues
Revenues
50000 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
20000 usd
us-gaap Cost Of Revenue
CostOfRevenue
9500 usd
us-gaap Cost Of Revenue
CostOfRevenue
20000 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
30000 usd
us-gaap Gross Profit
GrossProfit
25300 usd
us-gaap Gross Profit
GrossProfit
30000 usd
CY2023Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
18000 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
0 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
18000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13502 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
47429 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13502 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
31502 usd
us-gaap Operating Expenses
OperatingExpenses
47429 usd
us-gaap Operating Expenses
OperatingExpenses
31502 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1502 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22129 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1502 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1502 usd
us-gaap Net Income Loss
NetIncomeLoss
-22129 usd
us-gaap Net Income Loss
NetIncomeLoss
-1502 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7333333 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7333333 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5000000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6166667 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6166667 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5000000 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1873 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
983 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2856 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
140000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-23112 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
119744 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
0 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1502 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2502 usd
us-gaap Net Income Loss
NetIncomeLoss
-22129 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-0 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4208 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
0 usd
NONE Increase Decrease Related Party Payable
IncreaseDecreaseRelatedPartyPayable
2000 usd
NONE Increase Decrease Related Party Payable
IncreaseDecreaseRelatedPartyPayable
0 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
0 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-14800 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10100 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37721 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
8598 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
140000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
140000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
102279 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
8598 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22099 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
124378 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8598 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_zZNxvo1zeUq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Use of Estimates</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management uses estimates and assumptions in preparing these financial statements in accordance with US GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities in the balance sheets, and the reported revenue and expenses during the periods reported. Actual results may differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
4000 usd
CY2023Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
4000 usd
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2023Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14800 usd
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0 usd
CY2024Q2 NONE Commission Percent
CommissionPercent
0.30
us-gaap Payments For Commissions
PaymentsForCommissions
0 usd
us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<p id="xdx_847_eus-gaap--RevenueRecognitionDeferredRevenue_zFKSi9rQoO78" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Deferred Revenue</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred revenue consists of payments made in advance of services provided to customers. The deferred revenue balances as of April 30, 2024 and October 31, 2023 are $<span id="xdx_903_eus-gaap--DeferredRevenueCurrent_iI_c20240430_zGCfAQqRQfEg">0</span> and $<span id="xdx_90E_eus-gaap--DeferredRevenueCurrent_iI_c20231031_zQJu5yQZaurd">14,800</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14800 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12000000 shares
us-gaap Operating Lease Expense
OperatingLeaseExpense
8742 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
4017 usd
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-004159-index-headers.html Edgar Link pending
0001683168-24-004159-index.html Edgar Link pending
0001683168-24-004159.txt Edgar Link pending
0001683168-24-004159-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gmtech_ex3101.htm Edgar Link pending
gmtech_ex3102.htm Edgar Link pending
gmtech_ex3200.htm Edgar Link pending
gmtech_i10q-043024.htm Edgar Link pending
MetaLinks.json Edgar Link pending
none-20240430.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
none-20240430_def.xml Edgar Link unprocessable
none-20240430_pre.xml Edgar Link unprocessable
none-20240430_lab.xml Edgar Link unprocessable
gmtech_i10q-043024_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
none-20240430_cal.xml Edgar Link unprocessable